BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 15311558)

  • 21. Trastuzumab/chemotherapy combinations in metastatic breast cancer.
    Ligibel JA; Winer EP
    Semin Oncol; 2002 Jun; 29(3 Suppl 11):38-43. PubMed ID: 12138396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer.
    Raff JP; Rajdev L; Malik U; Novik Y; Manalo JM; Negassa A; Hopkins U; Sarta C; Sparano JA
    Clin Breast Cancer; 2004 Feb; 4(6):420-7. PubMed ID: 15023243
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
    Esteva FJ; Valero V; Booser D; Guerra LT; Murray JL; Pusztai L; Cristofanilli M; Arun B; Esmaeli B; Fritsche HA; Sneige N; Smith TL; Hortobagyi GN
    J Clin Oncol; 2002 Apr; 20(7):1800-8. PubMed ID: 11919237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer.
    Hurley J; Doliny P; Reis I; Silva O; Gomez-Fernandez C; Velez P; Pauletti G; Powell JE; Pegram MD; Slamon DJ
    J Clin Oncol; 2006 Apr; 24(12):1831-8. PubMed ID: 16549824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer.
    Bianchini G; Kiermaier A; Bianchi GV; Im YH; Pienkowski T; Liu MC; Tseng LM; Dowsett M; Zabaglo L; Kirk S; Szado T; Eng-Wong J; Amler LC; Valagussa P; Gianni L
    Breast Cancer Res; 2017 Feb; 19(1):16. PubMed ID: 28183321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial.
    Lara PN; Laptalo L; Longmate J; Lau DH; Gandour-Edwards R; Gumerlock PH; Doroshow JH; Gandara DR;
    Clin Lung Cancer; 2004 Jan; 5(4):231-6. PubMed ID: 14967075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.
    Joensuu H; Kellokumpu-Lehtinen PL; Bono P; Alanko T; Kataja V; Asola R; Utriainen T; Kokko R; Hemminki A; Tarkkanen M; Turpeenniemi-Hujanen T; Jyrkkiö S; Flander M; Helle L; Ingalsuo S; Johansson K; Jääskeläinen AS; Pajunen M; Rauhala M; Kaleva-Kerola J; Salminen T; Leinonen M; Elomaa I; Isola J;
    N Engl J Med; 2006 Feb; 354(8):809-20. PubMed ID: 16495393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2-expressing human breast cancer cell lines.
    Merlin JL; Barberi-Heyob M; Bachmann N
    Ann Oncol; 2002 Nov; 13(11):1743-8. PubMed ID: 12419746
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interaction between Herceptin and taxanes.
    Diéras V; Beuzeboc P; Laurence V; Pierga JY; Pouillart P
    Oncology; 2001; 61 Suppl 2():43-9. PubMed ID: 11694787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer.
    Burris HA
    Semin Oncol; 2001 Feb; 28(1 Suppl 3):38-44. PubMed ID: 11301373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.
    Bullock K; Blackwell K
    Oncologist; 2008 May; 13(5):515-25. PubMed ID: 18515736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer.
    Takada K; Kashiwagi S; Goto W; Asano Y; Morisaki T; Fujita H; Takashima T; Ohsawa M; Hirakawa K; Ohira M
    Anticancer Res; 2018 Apr; 38(4):2285-2294. PubMed ID: 29599351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278).
    Guarneri V; Frassoldati A; Bruzzi P; D'Amico R; Belfiglio M; Molino A; Bertetto O; Cascinu S; Cognetti F; Di Leo A; Pronzato P; Crinó L; Agostara B; Conte P
    Clin Breast Cancer; 2008 Oct; 8(5):453-6. PubMed ID: 18952561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer.
    Baselga J; Swain SM
    Clin Breast Cancer; 2010 Dec; 10(6):489-91. PubMed ID: 21147694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer.
    Infante JR; Yardley DA; Burris HA; Greco FA; Farley CP; Webb C; Spigel DR; Hainsworth JD
    Clin Breast Cancer; 2009 Feb; 9(1):23-8. PubMed ID: 19299236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
    Wardley AM; Pivot X; Morales-Vasquez F; Zetina LM; de Fátima Dias Gaui M; Reyes DO; Jassem J; Barton C; Button P; Hersberger V; Torres AA
    J Clin Oncol; 2010 Feb; 28(6):976-83. PubMed ID: 20038734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Docetaxel (Taxotere) in combination with trastuzumab (Herceptin)].
    Ficorella C
    Tumori; 2001; 87(1 Suppl 2):S10-8. PubMed ID: 11357872
    [No Abstract]   [Full Text] [Related]  

  • 38. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
    Swain SM; Baselga J; Kim SB; Ro J; Semiglazov V; Campone M; Ciruelos E; Ferrero JM; Schneeweiss A; Heeson S; Clark E; Ross G; Benyunes MC; Cortés J;
    N Engl J Med; 2015 Feb; 372(8):724-34. PubMed ID: 25693012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer.
    Ewer MS; O'Shaughnessy JA
    Clin Breast Cancer; 2007 Jun; 7(8):600-7. PubMed ID: 17592672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.